Johnson & Johnson
Headline intensities
Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.
OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.
EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?
PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.
Climate action evidence
1 record · 1 source- Avoidance / reductions1 tCO2e(100%)
- 1 tCO2e
- · berkeley_voluntary_registry
Targets
Near-term
3 targets| Scope | Base | Target | Reduction | Alignment | Progress | Status |
|---|---|---|---|---|---|---|
| Scope 1 + 2Absolute | 2021 | 2030 | −44% | 1.5°C | insufficient data | — |
| Scope 1 + 2 + 3Absolute | 2021 | 2030 | −44% | In corporate strategy | insufficient data | — |
| Scope 3 | 2021 | 2028 | −80% | insufficient data | — |
Net zero
1 target| Scope | Base | Target | Reduction | Alignment | Progress | Status |
|---|---|---|---|---|---|---|
| Scope 1 + 2 + 3 | 2021 | 2045 | — | In corporate strategy | absolute-value target | — |
We haven't fully researched Johnson & Johnson yet.
Request a full evidence-chained profile — we'll dig into their carbon, nature, social & water disclosure, find their facilities and sources, and email you when it's ready.
We’ll only use your email to notify you about this request.
Latest news· last 5 of 7
full news log →- 2024Planned acquisition of Intra-Cellular Therapies (~$14.6B)
- 2024$5.1B talc litigation charge in 2024 (additional)
- 2024Acquired V-Wave for $0.6B upfront
- 2024Acquired Proteologix for ~$0.8B
- 2024Acquired Shockwave Medical for ~$13.1B